Passive immunity in prevention and treatment of infectious diseases
Open accessAbstract
Antibodies have been used for over a century in the prevention and treatment of infectious disease. They are used most commonly for the prevention of measles, hepatitis A, hepatitis B, tetanus, varicella, rabies, and vaccinia. Although their use in the treatment of bacterial infection has largely been supplanted by antibiotics, antibodies remain a critical component of the treatment of diptheria, tetanus, and botulism. High-dose intravenous immunoglobulin can be used to treat certain viral infections in immunocompromised patients (e.g., cytomegalovirus, parvovirus B19, and enterovirus infections). Antibodies may also be of value in toxic shock syndrome, Ebola virus, and refractory staphylococcal infections. Palivizumab, the first monoclonal antibody licensed (in 1998) for an infectious disease, can prevent respiratory syncytial virus infection in high-risk infants. The development and use of additional monoclonal antibodies to key epitopes of microbial pathogens may further define protective humoral responses and lead to new approaches for the prevention and treatment of infectious diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Identification of antigen-specific antibodies after immunization can readily inform vaccine design since such antibodies can be used to confer passive immunity.
“Identification of antigen-specific antibodies after immunization can readily inform vaccine design since such antibodies can be used to confer passive immunity [218].”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 202 · Cited by 388
Research works printed but not linked: 13
- [5]5. American Academy of Pediatrics. 1997. Diphtheria, p. 191-195. In G. Peter (ed.), 1997 Red Book. Report of the Committee on Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [7]7. American Academy of Pediatrics. 1997. Tetanus, p. 518-523. In G. Peter (ed.), 1997 Red Book. Report of the Committee on Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [9]9. American Academy of Pediatrics. 1997. Hepatitis A, p. 237-246. In G. Peter (ed.), 1997 Red Book. Report of the Committee on Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [8]8. American Academy of Pediatrics. 1997. Clostridial infections, p. 174-178. In G. Peter (ed.), 1997 Red Book. Report of the Committee on Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [10]10. American Academy of Pediatrics. 1997. Hepatitis B, p. 247-260. In G. Peter (ed.), 1997 Red Book. Report of the Committee on Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [12]12. American Academy of Pediatrics. 1997. Herpes simplex, p. 266-276. In G. Peter (ed.), 1997 Red Book. Report of the Committee of Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [11]11. American Academy of Pediatrics. 1997. Measles, p. 344-357. In G. Peter (ed.), 1997 Red Book. Report of the Committee of Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [13]13. American Academy of Pediatrics. 1997. Rubella, p. 456-462. In G. Peter (ed.), 1997 Red Book. Report of the Committee of Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- [121]121. Nef, J. M. 1995. DNA viruses, Poxviridae, p. 1325. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
- [125]125. Ochs, H. D., and J. Winkelstein. 1996. Disorders of the B-cell system, p. 296-338. In E. R. Stiehm (ed.), Immunologic disorders in infants and children, 4th ed. The W. B. Saunders Co., Philadelphia, Pa.
- [148]148. Sandberg, E. T., M. W. Kline, and W. T. Shearer. 1996. The secondary immunodeficiencies, p. 553-601. In E. R. Stiehm (ed.), Immunologic disorders in infants and children, 4th ed. The W. B. Saunders Co., Philadelphia, Pa.
- [165]165. Stiehm, E. R. 1998. Passive Immunization, p. 2769-2802. In R. D. Feigin and J. D. Cherry (ed.), Textbook of pediatric infectious diseases, 4th ed. The W. B. Saunders Co., Philadelphia, Pa.
- [189]189. Wilson, C. B., D. B. Loius, and L. A. Penix. 1996. The physiologic immunodeficiency of immaturity, p. 253-295. In E. R. Stiehm (ed.), Immunologic disorders in infants and children, 4th ed. The W. B. Saunders Co., Philadelphia, Pa.
- Authors
- Keller, M. A., & Stiehm, E. R.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2000-10
- Volume
- 13
- Issue
- 4
- Pages
- 602-614
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC88952
- OpenAlex
- W2140471823
- Cited by
- 388
- References
- 202
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 12 · 2022: 15 · 2021: 26 · 2020: 23 · 2019: 10 · 2018: 26 · 2017: 21 · 2016: 18 · 2015: 19 · 2014: 21 · 2013: 14 · 2012: 22
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Historical Medical Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- passive immunity, immunoglobulins, monoclonal antibodies, palivizumab, intravenous immunoglobulin, measles, hepatitis B, tetanus, rabies, diphtheria, botulism, cytomegalovirus, parvovirus B19, enterovirus infection, toxic shock syndrome, Ebola virus, staphylococcal infections, respiratory syncytial virus, immunocompromised patients, humoral immunity
- MeSH terms
- Animals, Antibodies, Bacterial, Antibodies, Viral, Bacterial Infections, Humans, Immunization, Passive, Virus Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
